// App-Quantinova.ai

e17560 : Recombinant human adenovirus p53 injection enhanced sensitivity of chemotherapeutics through DNA damage response pathway in advanced papillary thyroid cancer in vitro and in vivo.

Researchers

Presenter

  • Jingqiang Zhu

Principal Investigators

  • Zhimian Huang

  • Wenshuang Wu

Medical Centers

  • West China Hospital of Sichua University, Chengdu, China

  • The Seventh High School in Chengdu, Chengdu, China

  • Sichuan University Huaxi Hospital, Chengdu, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Papillary carcinoma

Biomarkers

  • p53

  • Patched 1

Drug/Treatment

  • Paclitaxel

  • Cisplatin

  • rAd/P53

  • rAd-p53

  • TPC-1

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved